Androgensa | Older affected sibling’s sex | Outcomes | |||||||
---|---|---|---|---|---|---|---|---|---|
12-month AOSI | 36-month SRS | ||||||||
Beta | 95% CI | P | P b | Beta | 95% CI | P | P b | ||
ln(T) | Female (n = 22) | 0.91 | (0.20,1.63) | 0.02 | 0.008 | 0.61 | (0.27,0.94) | 0.001 | 0.006 |
Male (n = 115) | 0.08 | (−0.16, 0.32) | 0.50 | −0.08 | (−0.30,0.14) | 0.47 | |||
ln(A4) | Female (n = 22) | 0.22 | (−1.88,2.33) | 0.82 | 0.84 | 1.10 | (−0.07,2.28) | 0.06 | 0.06 |
Male (n = 115) | 0.05 | (−0.22,0.33) | 0.70 | −0.23 | (−0.48,0.02) | 0.07 | |||
ln(DHEA) | Female (n = 22) | 0.39 | (−0.40,1.18) | 0.32 | 0.36 | 0.18 | (−0.26,0.61) | 0.40 | 0.68 |
Male (n = 115) | 0.02 | (−0.20,0.24) | 0.86 | −0.06 | (−0.26,0.14) | 0.57 |